Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Gilberto De Lima Lopes, MD
Advertisement
Articles by Gilberto De Lima Lopes, MD
Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).
Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.
Advertisement
Latest Updated Articles
Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung CancerPublished: May 20th 2020 | Updated:
- Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer
Published: May 21st 2020 | Updated:
Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung CancerPublished: February 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5